David B Henley

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. doi Adverse events and dropouts in Alzheimer's disease studies: what can we learn?
    David B Henley
    Lilly Research Laboratories, Indianapolis, IN, USA Electronic address
    Alzheimers Dement 11:24-31. 2015
  2. doi Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studies
    David B Henley
    Lilly Research Laboratories, Indianapolis, IN, USA
    Alzheimers Dement 8:407-16. 2012
  3. doi Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease
    David B Henley
    Eli Lilly and Company, Lilly Corporate Center, Clinical Research Physician, Alzheimer s Team, DC 6161, Indianapolis, IN 46285 6161, USA
    Expert Opin Pharmacother 10:1657-64. 2009
  4. doi Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings
    David B Henley
    Lilly Research Laboratories, Indianapolis, IN, USA
    Curr Med Res Opin 30:2021-32. 2014

Collaborators

Detail Information

Publications4

  1. doi Adverse events and dropouts in Alzheimer's disease studies: what can we learn?
    David B Henley
    Lilly Research Laboratories, Indianapolis, IN, USA Electronic address
    Alzheimers Dement 11:24-31. 2015
    ..In elderly participants, AE rates, dropouts, and deaths are important considerations as they may undermine the validity of clinical trials. Published discontinuation and safety data are limited...
  2. doi Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studies
    David B Henley
    Lilly Research Laboratories, Indianapolis, IN, USA
    Alzheimers Dement 8:407-16. 2012
    ..An understanding of expected rates of adverse events (AEs), overall discontinuations, and discontinuations due to AEs, serious AEs, and deaths would be useful in planning such trials...
  3. doi Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease
    David B Henley
    Eli Lilly and Company, Lilly Corporate Center, Clinical Research Physician, Alzheimer s Team, DC 6161, Indianapolis, IN 46285 6161, USA
    Expert Opin Pharmacother 10:1657-64. 2009
    ..Therefore, pharmacological agents that reduce A beta formation may be of therapeutic benefit...
  4. doi Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings
    David B Henley
    Lilly Research Laboratories, Indianapolis, IN, USA
    Curr Med Res Opin 30:2021-32. 2014
    ..To assist in future development of γ-secretase inhibitors, we report detailed safety findings from the IDENTITY study, with emphasis on those that might be mechanistically linked to γ-secretase inhibition...